 Home > Active Ingredient News > Antitumor Therapy > Lancet Respirat Med: The third-generation tyrosine kinase inhibitor Furmonertinib has a promising effect in NSCLC patients with EGFR T790M mutation!

Lancet Respirat Med: The third-generation tyrosine kinase inhibitor Furmonertinib has a promising effect in NSCLC patients with EGFR T790M mutation!

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

pinworm medicine target

chlordiazepoxide 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Furmonertinib (Furatinib, AST2818) is a three-representative skin growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets sensitized EGFR and EGFR Thr790Met (T790M) mutations .

Furmonertinib (Furatinib, AST2818) is a three-representative skin growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets sensitized EGFR and EGFR Thr790Met (T790M) mutations

This study aims to evaluate the efficacy and safety of Furmonertinib in advanced non-small cell lung cancer ( NSCLC ) patients with EGFR T790M mutation .

NSCLC

This is a single-arm, open-label Phase 2b trial conducted in 46 hospitals in mainland China, recruiting locally advanced or metastatic EGFR T790M mutations that have progressed after first-generation or second-generation EGFR TKI treatment.

Condition improvement

From June 4, 2018 to December 8, 2018, a total of 220 patients received Furmonertinib treatment, all of which were included in the efficacy and safety analysis.

The median follow-up duration was 9.

Progression-free survival

Adverse events of grade 3 and above occurred in 58 (26%) patients, and treatment-related adverse events of grade 3 and above occurred in 25 (11%) patients .

Treatment-related grade 3 and above adverse events occurred in 25 (11%) patients

Treatment-related adverse events

Ten (5%) patients reported treatment-related diarrhea, and 16 (7%) patients reported treatment-related macula, all of grade 1-2.

Ten (5%) patients reported treatment-related diarrhea, and 16 (7%) patients reported treatment-related macula, all grade 1-2.

Furmonertinib shows good efficacy and acceptable safety in NSCLC patients with EGFR T790M mutation

Original source:

Yuankai Shi, et al.

org/10.
1016/S2213-2600(20)30455-0" target="_blank" rel="noopener">Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.